机构：[1]Department of Urology, Changhai Hospital, Second Military Medical University,Shanghai, China[2]Center for Translational Medicine, Second Military MedicalUniversity, Shanghai, China[3]Shanghai Key Laboratory of Cell Engineering, Shanghai,China[4]Department of Genetics, Washington University School of Medicine, St Louis,MO, USA[5]The Edison Family Center for Genome Sciences and Systems Biology,Washington University School of Medicine, St Louis, MO, USA[6]Novogene Co, Ltd,Beijing, China[7]Department of Pathology, Changhai Hospital, Second Military MedicalUniversity, Shanghai, China[8]CAS Key Laboratory of Tissue Microenvironment andTumor, Shanghai Institute of Nutrition and Health, Shanghai Institutes for BiologicalSciences, University of Chinese Academy of Sciences, Chinese Academy of Sciences,Shanghai, China[9]Department of Urology, Changzheng Hospital, Second MilitaryMedical University, Shanghai, China[10]Department of Radiology, Changhai Hospital,Second Military Medical University, Shanghai, China[11]Department of Urology, FirstAffiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China[12]StateKey Laboratory of Reproductive Medicine and Department of Urology, the FirstAffiliated Hospital of Nanjing Medical University, Nanjing, China[13]Department ofUrology, Institute of Surgery Research, Daping Hospital, Third Military MedicalUniversity, Chongqing, China[14]Department of Histology and Embryology, SecondMilitary Medical University, Shanghai, China[15]Department of Urology, First AffiliatedHospital of Anhui Medical University, Hefei, China[16]Department of Urology, FirstAffiliated Hospital of Soochow University, Suzhou, China[17]Department of Urology,Xuzhou Central Hospital, The Affiliated Xuzhou Hospital of Medical College ofSoutheast University, Xuzhou, China[18]Department of Urology, Zhongda Hospital,Southeast University, Nanjing, China[19]Department of Urology, Gongli Hospital, SecondMilitary Medical University, Shanghai, China[20]Department of Urology, ZhejiangProvincial People’s Hospital, Hangzhou Medical College, Hangzhou, China[21]Department of Urology Institute of Shenzhen University, Shenzhen Luohu People’sHospital, Shenzhen, China深圳市康宁医院深圳医学信息中心[22]Department of Urology, First Affiliated Hospital ofZhengzhou University, Zhengzhou, China[23]Department of Urology, Shaoxing CentralHospital, Shaoxing, China[24]Department of Urology, Shishi Hospital, Shishi, China[25]Department of Urology, The Affiliated Hospital of Hebei University, Baoding, China河北大学附属医院[26]Department of Urology, Huadong Hospital, Fudan University, Shanghai, China[27]Department of Urology, Tongji Hospital, Tongji Medical College Huazhong Universityof Science and Technology, Wuhan, China华中科技大学同济医学院附属同济医院
Prostate cancer is the second most common cancer in men worldwide(1). Over the past decade, large-scale integrative genomics efforts have enhanced our understanding of this disease by characterizing its genetic and epigenetic landscape in thousands of patients(2,3). However, most tumours profiled in these studies were obtained from patients from Western populations. Here we produced and analysed whole-genome, whole-transcriptome and DNA methylation data for 208 pairs of tumour tissue samples and matched healthy control tissue from Chinese patients with primary prostate cancer. Systematic comparison with published data from 2,554 prostate tumours revealed that the genomic alteration signatures in Chinese patients were markedly distinct from those of Western cohorts: specifically, 41% of tumours contained mutations in FOXA1 and 18% each had deletions in ZNF292 and CHD1. Alterations of the genome and epigenome were correlated and were predictive of disease phenotype and progression. Coding and noncoding mutations, as well as epimutations, converged on pathways that are important for prostate cancer, providing insights into this devastating disease. These discoveries underscore the importance of including population context in constructing comprehensive genomic maps for disease. Genomic, transcriptomic and DNA methylation data from tissue samples from 208 Chinese patients with prostate cancer define the landscape of alterations in this population, and comparison with data from Western cohorts suggests that the disease may stratify into different molecular subtypes.
基金：
'Key Research and Development Project on Precision Medicine' fund - Chinese Ministry of Science and Technology [2016YFC090220]; Shanghai Key Laboratory of Cell Engineering [14DZ2272300]; Shanghai 'Top Priority' Medical Center Project [2017ZZ01005]; 'National Major New Drug Discovery Initiative' Fund - '13th Five-Year Plan' (Subproject) [2017ZX093040300002]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China [81602467]; 'Zhangjiang National Innovation Demonstration Zone' Initiative Development Fund; American Cancer SocietyAmerican Cancer Society [RSG-14-049-01-DMC, PF-17-201-01]
第一作者机构：[1]Department of Urology, Changhai Hospital, Second Military Medical University,Shanghai, China[2]Center for Translational Medicine, Second Military MedicalUniversity, Shanghai, China[3]Shanghai Key Laboratory of Cell Engineering, Shanghai,China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Urology, Changhai Hospital, Second Military Medical University,Shanghai, China[3]Shanghai Key Laboratory of Cell Engineering, Shanghai,China[4]Department of Genetics, Washington University School of Medicine, St Louis,MO, USA[5]The Edison Family Center for Genome Sciences and Systems Biology,Washington University School of Medicine, St Louis, MO, USA
推荐引用方式(GB/T 7714)：
Jing Li,Chuanliang Xu,Hyung Joo Lee,et al.A genomic and epigenomic atlas of prostate cancer in Asian populations[J].NATURE.2020,580(7801):93-+.doi:10.1038/s41586-020-2135-x.
APA：
Jing Li,Chuanliang Xu,Hyung Joo Lee,Shancheng Ren,Xiaoyuan Zi...&Yinghao Sun.(2020).A genomic and epigenomic atlas of prostate cancer in Asian populations.NATURE,580,(7801)
MLA：
Jing Li,et al."A genomic and epigenomic atlas of prostate cancer in Asian populations".NATURE 580..7801(2020):93-+
综合性期刊